国际肺癌研究协会关于2019冠状病毒病对国际肺癌临床试验影响的研究
该研究通过数据收集调查和行动调查评估COVID-19对全球肺癌试验的影响。2019至2020年全球入组下降14%,主要发生在4至6月,单个中心入组显著减少(p=0.0309);最常见挑战为合格患者减少(63%)、方案依从性下降(56%)和试验暂停(54%)。缓解策略包括远程医疗访视(45%)等,最有效策略为远程知情同意(89%)、远程医疗访视(85%)等。
要点
- 2019至2020年全球肺癌试验入组下降14%,主要发生在4至6月。
- 行动调查(N=172)显示最常见挑战为合格患者减少(63%)、方案依从性下降(56%)、试验暂停(54%)。
- 最有效缓解策略包括远程知情同意(89%)、远程医疗访视(85%)、远程患者报告症状收集(85%)、院外操作(85%)。
核心结论
- COVID-19大流行给肺癌临床试验的实施和入组带来了许多挑战。
- 尽管大流行恶化,试验入组有所改善。
- 作者认为更灵活的方法可能改善入组和临床试验的可及性,甚至在大流行之后也是如此。
研究设计与样本
- 数据收集调查收集了2019至2020年294项全球肺癌试验的每月汇总入组数据。
- 64个问题的行动调查评估了COVID-19对临床试验的影响并确定了实施的缓解策略(N=172)。
主要发现
- 2019至2020年全球临床试验入组下降14%。
- 入组减少主要发生在4至6月,单个中心入组显著减少(p=0.0309)。
- 2019年10月至12月与2020年同期入组无显著差异(p=0.25)。
- 行动调查(N=172)中最常见挑战为合格患者减少(63%)、方案依从性下降(56%)、试验暂停(54%)。
- 患者相关挑战包括进入试验中心(49%)、旅行能力(54%)、访问中心意愿(59%)。
关键数值与推荐
- 最常见缓解策略包括修改监测要求(47%)、远程医疗访视(45%)、修改所需访视(25%)、邮购药物(25%)、在非研究机构进行实验室(27%)和放射学(21%)检查。
- 中心认为最有效的缓解策略为远程医疗访视(85%)、远程患者报告症状收集(85%)、院外操作(85%)、远程知情同意(89%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To evaluate the effects of the global coronavirus disease 2019 (COVID-19) pandemic on lung cancer trials, we surveyed investigators and collected aggregate enrollment data for lung cancer trials across the world before and during the pandemic. METHODS: A Data Collection Survey collected aggregate monthly enrollment numbers from 294 global lung cancer trials for 2019 to 2020. A 64-question Action Survey evaluated the impact of COVID-19 on clinical trials and identified mitigation strategies implemented. RESULTS: Clinical trial enrollment declined from 2019 to 2020 by 14% globally. Most reductions in enrollment occurred in April to June where we found significant decreases in individual site enrollment (p = 0.0309). Enrollment was not significantly different in October 2019 to December of 2019 versus 2020 (p = 0.25). The most frequent challenges identified by the Action Survey (N = 172) were fewer eligible patients (63%), decrease in protocol compliance (56%), and suspension of trials (54%). Patient-specific challenges included access to trial site (49%), ability to travel (54%), and willingness to visit the site (59%). The most frequent mitigation strategies included modified monitoring requirements (47%), telehealth visits (45%), modified required visits (25%), mail-order medications (25%), and laboratory (27%) and radiology (21%) tests at nonstudy facilities. Sites that felt the most effective mitigation strategies were telehealth visits (85%), remote patient-reported symptom collection (85%), off-site procedures (85%), and remote consenting (89%). CONCLUSIONS: The COVID-19 pandemic created many challenges for lung cancer clinical trials conduct and enrollment. Mitigation strategies were used and, although the pandemic worsened, trial enrollment improved. A more flexible approach may improve enrollment and access to clinical trials, even beyond the pandemic.
引用
- Smeltzer MP, Scagliotti GV, Wakelee HA, et al. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials. J Thorac Oncol. 2022. PMID: 35183774. doi:10.1016/j.jtho.2022.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。